Purdue subsidiary nabs non-opioid drug for pain; OrbiMed backs small biotech's 'superior' drug
As Purdue Pharma reaches the final stages of a massive bankruptcy deal centered around its responsibility in the opioid crisis, one of its subsidiaries is quietly building a portfolio of non-opioid treatments for pain.
Stamford, CT-based Imbrium has exercised its option to license what’s formerly known as ALV-107 from PureTech Health, whose affiliate Alivio Therapeutics had devised a way to bind selectively to inflamed tissue and achieve targeted immunomodulation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.